ID
23026
Description
NCT00340080 / VIIV-CNA106030 https://clinicaltrials.gov/ct2/show/NCT00340080 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Week 2 Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV
Link
https://clinicaltrials.gov/ct2/show/NCT00340080
Keywords
Versions (1)
- 6/20/17 6/20/17 -
Uploaded on
June 20, 2017
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Genetic Screening For HLA-B*5701 n Patients with HIV Week 2 NCT00340080
Genetic Screening For HLA-B*5701 Week 2 NCT00340080
- StudyEvent: ODM
Similar models
Genetic Screening For HLA-B*5701 Week 2 NCT00340080
- StudyEvent: ODM
C0449788 (UMLS CUI [1,2])
C0019993 (UMLS CUI [1,2])
C0019993 (UMLS CUI [1,2])
C0449788 (UMLS CUI [1,3])
C0019993 (UMLS CUI [1,2])
C0019993 (UMLS CUI [1,2])
C0449788 (UMLS CUI [1,3])
C0008952 (UMLS CUI [1,2])
C0008952 (UMLS CUI [1,2])
C0449788 (UMLS CUI [1,3])
C0449788 (UMLS CUI [1,2])
C0449788 (UMLS CUI [1,2])
C0449788 (UMLS CUI [1,2])
No comments